Abstract: Provided herein are processes for manufacturing recombinant ranibizumab or a ranibizumab variant that include providing a liquid comprising recombinant ranibizumab or a ranibizumab variant that is substantially free of cells; capturing the recombinant ranibizumab or the ranibizumab variant in the liquid using an affinity chromatography column, wherein the eluate of the affinity chromatography column comprises the recombinant ranibizumab or the ranibizumab variant; purifying the recombinant ranibizumab or the ranibizumab variant in the eluate of step (b) using a first cation exchange chromatography column and buffers that have a pH of about pH 5.5 to about 7.

Abstract: A table of clauses is compiled into a shareable database. Each clause relates to parties potentially affected by a use of the clause in a legal document. Each clause also includes authorizations controlling access and preferences specifying provisions and terms for a specific subject matter. A searchable index is formed using a topical ordering based on the specific subject matter included. A clause selection interface is exported and includes document drafting controls. The clauses table index is authenticated against the authorizations for a given user, preferences for the individual parties, and specified monetary amount and is presented following successful authentication. A clause selection is authenticated against the authorizations for a given user and the preferences for the parties. An individual clause from the clauses table is displayed on the user interface upon the selection by the given user following successful authentication.